Would you pay a premium for a drug that could reduce heart disease and lung cancer? Early evidence suggests that a juvenile arthritis drug might offer hope to people at high risk for heart attacks and strokes. The anti-inflammatory properties of canakinumab might prevent atherosclerosis that leads to heart attacks. getAbstract suggests this article to those with an interest in the inflammation theory of heart disease.
In this summary, you will learn
- Why the modest results of the canakinumab trial are important,
- How canakinumab works and
- Where the anti-inflammatory drug is in its experimental stages.
About the Author
Jennifer Couzin-Frankel, a Science Magazine staff writer since 2002, attended Harvard University.